GSK plc

10/15/2025 | Press release | Distributed by Public on 10/15/2025 10:16

Transaction notification (Form 6-K)


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2025
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the 'Company')
Transaction notification
​
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Emma Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£16.4000
1,355
£16.4000
1,531
£16.4000
1,038
d)
Aggregated information
Aggregated volume
Price
3,924
£16.4000
e)
Date of the transaction
2025-10-10
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Julie Brown
b)
Position/status
Chief Financial Officer
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£16.4000
680
£16.4000
584
d)
Aggregated information
Aggregated volume
Price
1,264
£16.4000
e)
Date of the transaction
2025-10-10
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Diana Conrad
b)
Position/status
Chief People Officer
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£16.4000
152
£16.4000
386
£16.4000
246
d)
Aggregated information

Aggregated volume
Price
784
£16.4000
e)
Date of the transaction
2025-10-10
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
James Ford
b)
Position/status
SVP and Group General Counsel, Legal and Compliance
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£16.4000
239
£16.4000
237
£16.4000
391
d)
Aggregated information

Aggregated volume
Price
867
£16.4000
e)
Date of the transaction
2025-10-10
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Sally Jackson
b)
Position/status
SVP, Global Communications and CEO Office
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£16.4000
242
£16.4000
149
£16.4000
133
d)
Aggregated information
Aggregated volume
Price
524
£16.4000
e)
Date of the transaction
2025-10-10
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Luke Miels
b)
Position/status
Chief Commercial Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£16.4000
365
£16.4000
578
£16.4000
727
d)
Aggregated information
Aggregated volume
Price
1,670
£16.4000
e)
Date of the transaction
2025-10-10
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Shobie Ramakrishnan
b)
Position/status
Chief Digital and Technology Officer
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W2044
b)
Nature of the transaction
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 9 October 2025 on ADSs held in the Company's Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$43.4400
119
$43.4400
112
$43.4400
186
d)
Aggregated information
Aggregated volume
Price
417
$43.4400
e)
Date of the transaction
2025-10-10
f)
Place of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
David Redfern
b)
Position/status
President, Corporate Development
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£16.4000
463
£16.4000
334
£16.4000
211
d)
Aggregated information
Aggregated volume
Price
1,008
£16.4000
e)
Date of the transaction
2025-10-10
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Regis Simard
b)
Position/status
President, Global Supply Chain
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£16.4000
309
£16.4000
557
£16.4000
268
d)
Aggregated information
Aggregated volume
Price
1,134
£16.4000
e)
Date of the transaction
2025-10-10
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Philip Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£16.4000
188
£16.4000
311
£16.4000
175
d)
Aggregated information
Aggregated volume
Price
674
£16.4000
e)
Date of the transaction
2025-10-10
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Deborah Waterhouse
b)
Position/status
CEO, ViiV Healthcare and President, Global Health, GSK
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£16.4000
427
£16.4000
482
£16.4000
290
d)
Aggregated information
Aggregated volum
Price
1,199
£16.4000
e)
Date of the transaction
2025-10-10
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Tony Wood
b)
Position/status
Chief Scientific Officer
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£16.4000
594
£16.4000
202
£16.4000
271
d)
Aggregated information
Aggregated volume
Price
1,067
£16.4000
e)
Date of the transaction
2025-10-10
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Emma Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in the Company's Performance Share Plan subject to a 2-year holding period
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£16.4000
4,590.351
£16.4000
4,196.389
d)
Aggregated information
Aggregated volume
Price
N/A (single transaction)
8,786.741
£16.4000
e)
Date of the transaction
2025-10-10
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
David Redfern
b)
Position/status
President Corporate Development
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held within an ISA
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£16.3499
20
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
e)
Date of the transaction
2025-10-10
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Victoria Whyte
b)
Position/status
Company Secretary
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held within an ISA
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£16.3499
17
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
e)
Date of the transaction
2025-10-10
f)
Place of the transaction
London Stock Exchange (XLON)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GSK plc
(Registrant)
Date: October 15, 2025
By:/s/ VICTORIA WHYTE
--------------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GSK plc
GSK plc published this content on October 15, 2025, and is solely responsible for the information contained herein. Distributed via EDGAR on October 15, 2025 at 16:16 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]